AG0018Q6

138402-11-6 | 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-

Chemical structure of 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, CAS 138402-11-6
AG0018Q6
sdsSDS
sdsCOA

Price

$0.00

WARNING This product is not for human or veterinary use.
Request For Quotation
CAS Number 138402-11-6
Catalog Number AG0018Q6(AGN-PC-0PMNVE)
Chemical Name 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
EC Number 604-078-2
IUPAC Name 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
InChI InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
InChI Key YOSHYTLCDANDAN-UHFFFAOYSA-N
MDL Number MFCD00864464
Molecular Formula C25H28N6O
Molecular Weight 428.5294
NSC Number 758696
SMILES O=C1C2(N=C(N1Cc1ccc(cc1)c1c(cccc1)c1[nH]nnn1)CCCC)CCCC2
UNII J0E2756Z7N
Synonyms
2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one, Aprovel, Avapro, BMS 186295, BMS-186295, irbesartan, Karvea, SR 47436, SR-47436, SR47436, irbesartan, 138402-11-6, Aprovel, Avapro, Karvea, SR-47436, BMS-186295, BMS 186295, Irbesartan [USAN:INN], SR 47436, UNII-J0E2756Z7N, CHEMBL1513, 8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one, CHEBI:5959, C25H28N6O, YOSHYTLCDANDAN-UHFFFAOYSA-N, J0E2756Z7N, MFCD00864464, 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one, 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one, NCGC00095122-01, AK-57149, DSSTox_CID_3169, 2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(4.4)non-1-en-4-one, 2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[4.4]non-1-en-4-one, 2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one, DSSTox_RID_76900, DSSTox_GSID_23169, 1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, Irbesarran, Lrbesartan, Irbetan, Irbesartan Krka, Irbesartan BMS, [3H]irbesartan, Irbesartan Winthrop, 2-BUTYL-3-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO[4.4]NON-1-EN-4-ONE, SMR000466306, Avapro (TN), CAS-138402-11-6, HSDB 8215, Irbesartan [USAN:USP:INN:BAN], Irbesartan(Avapro), Irbesartan ,(S), 2-butyl-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one, 3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one, Irbesartan (Avapro), Irbesartan(Avapro)/, PubChem21382, Spectrum_001751, AC1L1GMK, Spectrum2_001675, Spectrum3_000994, Spectrum4_001122, Spectrum5_001288, SCHEMBL4246, 2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one, BSPBio_002687, GTPL589, KBioGR_001603, KBioSS_002231, MLS000759408, MLS001424099, BIDD:GT0347, SPECTRUM1504259, SPBio_001889, GTPL6908, Jsp002315, DTXSID0023169, Irbesartan (JP17/USAN/INN), KBio2_002231, KBio2_004799, KBio2_007367, KBio3_001907, KS-00000ISW, EBD8758, BCPP000202, HMS1922J05, HMS2051L08, HMS2093E16, HMS2232F23, HMS3370B06, HMS3393L08, HMS3715L04, Pharmakon1600-01504259, BCP02004, HY-B0202, ZINC3872931, Tox21_111433, ABP000523, AC-537, BDBM50042235, CCG-39091, NSC758696, STK645362, AKOS005576396, AKOS015895353, Irbesartan, >=98% (HPLC), powder, Tox21_111433_1, AB07472, AM90289, BCP9000792, CCG-101012, CS-2140, DB01029, KS-1151, MCULE-9617953373, NC00262, NSC-758696, NCGC00095122-02, NCGC00095122-03, NCGC00095122-05, 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one, 4CA-0654, AN-15743, BC207567, BR-57149, CPD000466306, H931, LS-60064, SAM001246548, SC-08814, SBI-0206769.P001, AB0013366, AB1009632, TL8000875, FT-0601598, I0859, S1507, ST24028252, C07469, D00523, J10394, S-1797, 54246-EP2270011A1, 54246-EP2295406A1, 54246-EP2295422A2, 54246-EP2298772A1, 54246-EP2298776A1, 54246-EP2298779A1, 54246-EP2301923A1, 54246-EP2301931A1, 54246-EP2305219A1, 54246-EP2308562A2, 54246-EP2308839A1, AB00639954-06, AB00639954_07, AB00639954_08, 402I116, A807387, L000319, SR-05000001997, I06-0690, Q-201249, SR-05000001997-1, (-)-Styrene glycol; (R)-(-)-Phenylethylene glycol, BRD-K60038276-001-02-5, BRD-K60038276-001-03-3, Irbesartan, European Pharmacopoeia (EP) Reference Standard, Irbesartan, United States Pharmacopeia (USP) Reference Standard, 2-butyl-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[, 2-butyl-3-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[, Irbesartan, Pharmaceutical Secondary Standard; Certified Reference Material, 2-butyl-3-[ p -( o -1 H -tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one, 2-(n-butyl)-3-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one, 2-Butyl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[4.4]non-1-en-4-one, 2-butyl-3-{[2''-(1H-tetrazol-5-yl)[1,1''-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-{[2''-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one, 2-n-butyl-3-<<2'-(1H-tetrazol-5-yl)biphenyl-4-yl>methyl>-1,3-diazaspiro<4.4>non-1-en-4-one;, 3-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one, 3-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one, 8-butyl-7-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one, Avalide, ifirmasta, Sabervel, Irbesartan HCl, Irbesartan D4, Irbesartan Zentiva, Aprovel (TN), Avalide (TN), Karvea (TN), Irbesartan hydrochloride, 2,4-Dichloropyrimidine, BMS Brand of Irbesartan, D00JAU, D0F8KG, Irbesartan (JAN/USAN/INN), CID3749, Bristol Myers Brand of Irbesartan, SanofiWinthrop Brand of Irbesartan, C25-H28-N6-O, CS-T-29592, SR47436, A5970, A10477, C081309, BMS-186295, SR-47436,Aprovel, Karvea, Irbesartan, D000077405, 3-BUTYL-2-[[4-[2-(2H-TETRAZOL-5-YL)PHENYL]PHENYL]METHYL]-2,4-DIAZASPIRO[4.4]NON-3-EN-1-ONE, 2-butyl-3-[ p-(o-1 H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one, 3-butyl-2-((4-(2-(2h-tetrazol-5-yl)phenyl)phenyl)methyl)-2,4-diazaspiro(4.4)non-3-en-1-one, Irbesartan, 99%, a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist - 1G 1g,

Related Research Chemicals

CERTIFICATE OF ANALYSIS
Chemical Name: Batch Number:
Chemical Structure: CAS Registry No:
Product ID:
Manufacture Date:
Storage Temperature:
Formula:
Molecular Weight:
Quantity:
Analysis Data:
Test: Result:
Conclusion: The above product meets the specifications of Angene.
Analyst:Chase
Date:
Reviewed by:Jessie
Date:
Angene International Limited